Clementia Pharmaceuticals' Series A Round

Clementia Pharmaceuticals raised a round of funding on January 09, 2014.

Clementia Pharmaceuticals (NASDAQ: CMTA) is a clinical stage biopharmaceutical company that is developing its lead candidate palovarotene, a novel RARĪ³ agonist, to treat Fibrodysplasia Ossificans Pro…

Articles about Clementia Pharmaceuticals' Series A Round: